A panel discussion titled "Convection of Knowledge in Life Science Business: Converting Accumulation of Large Corporations into Venture Power" (session partner: Kobe Medical Industry Development Organization) will be held during the 10th Conference of the Association for Hyperdifferent Fields, hosted by LIVANES (March 5-6, 2021 (Friday and Saturday)).

For life science startups originating from academia, the knowledge and expertise in R&D, production, and regulatory compliance that pharmaceutical companies and other MedTech-related companies have accumulated to date can be a major clue to accelerating commercialization. How can the MedTech area be revitalized by establishing a mechanism for the circulation of knowledge and know-how? In this session, we will discuss the creation of a new relationship between large companies and start-ups with experienced pharmaceutical company management and start-ups.

We will have a program of discussions among researchers, start-ups, and large companies from a variety of perspectives, not limited to the themes of this session.
We are now accepting applications for audience participation. Please visit the conference website (see below).

*The event will be held after taking measures against new coronavirus infection on the day of the event.For more information

Convection of Knowledge in Life Science Business - Transforming the Accumulation of Large Corporations into the Power of Ventures

Date: Saturday, March 6, 2021, 13:00-14:00
Location: Congress Square Haneda (Haneda Innovation City Zone J, 1-1-4 Haneda Airport, Ota-ku, Tokyo)
Details:https://hic.lne.st/conference/hic2021/

speaker

MyCan Technologies, Inc.
CEO
Kazuo Miyazaki

Graduated from Tokyo University of Science, Graduate School of Science. Specialized in synthetic organic chemistry and regenerative medicine. For about 20 years, he worked for a pharmaceutical company conducting exploratory research on small molecule compounds for vascular, renal, and central nervous system diseases, as well as small molecule compounds to complement regenerative medicine. His encounter with malaria, dengue fever, and other infectious diseases in India led him to establish MyCan Technologies, Inc. in 2016. Aiming to solve the challenges of special blood-borne infections using regenerative medicine technologies.

Cell Fiber Corporation
President and Representative Director
Yu Yanagisawa

Graduated from Tokyo University of Pharmacy and Life Sciences, Faculty of Life Sciences, Department of Environmental Life Sciences. D. (Engineering), Department of Chemical and Biological Engineering, Graduate School of Chemical and Biological Engineering, The University of Tokyo. engaged in planning and development work at RIVANES Corporation until March 2011. in March 2018, received the Dean's Award of the Graduate School of Engineering, The University of Tokyo and the President's Award of The University of Tokyo. since May 2018, appointed as Director of Cell Fiber. since June 2018, AMED "Cell Development of High Density Continuous Production Technology for Antibody Production Using Fiber" Principal Investigator.

Liberace Capital Inc.
board member
Nobuo Hanai

In 2003, he established BioWa, Inc. in the U.S. to out-license the antibody-related technologies he had developed, and was appointed president and responsible for company operations. He was appointed Chairman of the Board in 2018 and Chairman of the Board in 2019, He retired in March 2020 and became a director of Liverness Capital in May of the same year.

＜挨拶＞

Kobe Medical Industry Development Organization
managing director
Masafumi Mieno

He joined the City of Kobe in April 1990 and was assigned to the department promoting Kobe Medical Industry Development Project in 2012, where he has worked for more than 10 years to promote Kobe Medical Industry Development Project. In June 2020, he assumed the position of Executive Director of Kobe Medical Industry Development Organization (current position).

.

Leave a Nest Co., Ltd.
Executive Officer
Hiroyuki Takahashi

D. from Yokohama City University in 2009. D. in Science, focusing on creating new research projects between industry and young researchers, including the launch of the "Liberace Research Fund" for young researchers under the age of 40. In addition, he continues to organize the "Super Interdisciplinary Society," a place to generate new knowledge and seeds for research and development by combining individual knowledge, technology, and passion for problem solving without being bound by the framework of academia.